Biotek-snakken — Februar 2025
-
Og som sagt, den burde ikke stige mere end op til kurs måske 10-15 hvis vi strækker os langt.. igen, jeg kan sagtens se den stige til 15, men så er det mest fordi, aftalen betyder de styrker deres kapital beredskab og således forbedre forhandlings styrken ifm nye aftaler på pipeline.
-
Medix to submit final version of tesofensine application following interaction with COFEPRIS
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner Medix sees a clear regulatory path forward for tesofensine following discussions with the Mexican regulatory agency COFEPRIS.
Since the message from COFEPRIS, communicated in Saniona’s press releases of November 6 and November 12, 2024, Productos Medix S.A. de S.V. (Medix) has worked closely with COFEPRI
-
Photocure med glemt link
https://bladdercancer.libsyn.com/shining-a-blue-light-on-bladder-cancer-photocures-impact -
Meget snak om Tesofensine. Både omkring godkendelse, aftaler om udbredelse i Sydamerika og asien, samt patent. De er meget optimistiske omkring godkendelse. De tror at det kan blive i løbet af få måneder. Der blev talt om at det virkede som om at det drejede sig om "formatet" af de sidste data der skal leveres. Omvendt gjorde de et nummer ud af at pointere at de har alle oplysninger fra Medix og ikke selv har kontakt til Cofepris.
-
Her et link til interviewet: https://www.youtube.com/live/Df_VE2nly5Q
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind